Aadi Bioscience Inc reports results for the quarter ended in December - Earnings Summary

Whitehawk Therapeutics

28/03/2023 14:31

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 52 cents​​ per share for the quarter ended in December. The
mean expectation of five analysts for the quarter was for a loss
of 71 cents per share.
    * Revenue rose 427.7% to $5.28 million from a year ago;
analysts
expected $4.65 million. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 52 cents​.
    * The mean earnings estimate of analysts had fallen by
about 6.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Aadi Bioscience Inc shares had fallen by 43.5% this
quarter.
    * The company reported a quarterly loss of $13.92 million.
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $46.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 28 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.71          -0.52          Beat
 Sep. 30 2022      -0.74          -0.68          Beat
 Jun. 30 2022      -0.75          -0.87          Missed
 Mar. 31 2022      -0.71          -0.66          Beat